Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Daratumumab is an immunoglobulin G1 kappa (IgG1κ) human monoclonal antibody that binds to the CD38 antigen. Daratumumab is produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology. The molecular weight of daratumumab is approximately 148 kDa.
Hyaluronidase (recombinant human) is an endoglycosidase used to increase the dispersion and absorption of co-administered drugs when administered subcutaneously. It is a glycosylated single-chain protein produced by Chinese Hamster Ovary cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase (PH20). Hyaluronidase (recombinant human) has a molecular weight of approximately 61 kD.
Darzalex Faspro (daratumumab and hyaluronidase-fihj) injection is a sterile, preservative-free, colorless to yellow, and clear to opalescent solution supplied in a single-dose vial for subcutaneous administration.
Each Darzalex Faspro 15 mL single-dose vial contains 1,800 mg of daratumumab and 30,000 units of hyaluronidase , L-histidine (4.9 mg), L-histidine hydrochloride monohydrate (18.4 mg), L-methionine (13.5 mg), polysorbate 20 (6 mg), sorbitol (735.1 mg), and Water for Injection, USP.
DARZALEX FASPRO is indicated for the treatment of adult patients with multiple myeloma:
DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone is indicated for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.
This indication is approved under accelerated approval based on response rate [see Clinical Studies]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials [see WARNINGS AND PRECAUTIONS].
The recommended dose of DARZALEX FASPRO is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously over approximately 3-5 minutes. Tables 1, 2, 3, 4, and 5 provide the recommended dosing schedule when DARZALEX FASPRO is administered as monotherapy or as part of a combination therapy.
Use the dosing schedule provided in Table 1 when DARZALEX FASPRO is administered:
Table 1: DARZALEX FASPRO dosing schedule in combination with lenalidomide, pomalidomide or carfilzomib and dexamethasone (4-week cycle) and for monotherapy
| Weeks | Schedule |
| Weeks 1 to 8 | weekly (total of 8 doses) |
| Weeks 9 to 24a | every two weeks (total of 8 doses) |
| Week 25 onwards until disease progressionb | every four weeks |
| a First dose of the every-2-week dosing schedule is given at Week 9 b First dose of the every-4-week dosing schedule is given at Week 25 |
|
When DARZALEX FASPRO is administered as part of a combination therapy, see Clinical Studies and the prescribing information for dosage recommendations for the other drugs.
Use the dosing schedule provided in Table 2 when DARZALEX FASPRO is administered in combination with bortezomib, melphalan and prednisone (6-week cycle).
Table 2: DARZALEX FASPRO dosing schedule in combination with bortezomib, melphalan and prednisone (6-week cycle)
| Weeks | Schedule |
| Weeks 1 to 8 | weekly (total of 8 doses) |
| Weeks 9 to 24a | every two weeks (total of 8 doses) |
| Week 25 onwards until disease progressionb | every four weeks |
| a First dose of the every-3-week dosing schedule is given at Week 7 b First dose of the every-4-week dosing schedule is given at Week 55 |
|
When DARZALEX FASPRO is administered as part of a combination therapy, see Clinical Studies and the prescribing information for dosage recommendations for the other drugs.
Use the dosing schedule in Table 3 when DARZALEX FASPRO is administered in combination with bortezomib, thalidomide, and dexamethasone (4-week cycle).
Table 3: DARZALEX FASPRO dosing schedule in combination with bortezomib, thalidomide and dexamethasone (4-week cycle)
| Treatment phase | Weeks | Schedule |
| Induction | Weeks 1 to 8 | weekly (total of 8 doses) |
| Weeks 9 to 16a | every two weeks (total of 4 doses) | |
| Stop for high dose chemotherapy and ASCT | ||
| Consolidation | Weeks 1 to 8b | every two weeks (total of 4 doses) |
| a First dose of the every-2-week dosing schedule is given at Week 9 b First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT |
||
When DARZALEX FASPRO is administered as part of a combination therapy, see the prescribing information for dosage recommendations for the other drugs.
Use the dosing schedule in Table 4 when DARZALEX FASPRO is administered in combination with bortezomib, lenalidomide, and dexamethasone (4-week cycle) for treatment of newly diagnosed multiple myeloma patients eligible for autologous stem cell transplant (ASCT).
Table 4: DARZALEX FASPRO dosing schedule in combination with bortezomib, lenalidomide and dexamethasone (4-week cycle)
| Treatment phase | Weeks | Schedule |
| Induction | Weeks 1 to 8 | weekly (total of 8 doses) |
| Weeks 9 to 16a | every two weeks (total of 4 doses) | |
| Stop for high dose chemotherapy and ASCT | ||
| Consolidation | Weeks 1 to 8b | every two weeks (total of 4 doses) |
| a First dose of the every-2-week dosing schedule is given at Week 9 b First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following ASCT |
||
When DARZALEX FASPRO is administered as part of a combination therapy, see Clinical Studies and the prescribing information for dosage recommendations for the other drugs.
Use the dosing schedule in Table 5 when DARZALEX FASPRO is administered in combination with bortezomib and dexamethasone (3-week cycle).
Table 5: DARZALEX FASPRO dosing schedule in combination with bortezomib and dexamethasone (3-week cycle)
| Weeks 1 to 9 | weekly (total of 9 doses) |
| Weeks 10 to 24a | every three weeks (total of 5 doses) |
| Week 25 onwards until disease progressionb | every four weeks |
| a First dose of the every-3-week dosing schedule is given at Week 10 b First dose of the every-4-week dosing schedule is given at Week 25 |
|
When DARZALEX FASPRO is administered as part of a combination therapy, see the prescribing information for dosage recommendations for the other drugs.
The recommended dose of DARZALEX FASPRO is 1,800 mg/30,000 units (1,800 mg daratumumab and 30,000 units hyaluronidase) administered subcutaneously over approximately 3-5 minutes.
Use the dosing schedule provided in Table 6 when DARZALEX FASPRO is administered in combination with bortezomib, cyclophosphamide and dexamethasone (4-week cycle).
Table 6: DARZALEX FASPRO dosing schedule in combination with bortezomib, cyclophosphamide and dexamethasone (4-week cycle)
| Weeks | Schedule |
| Weeks 1 to 8 | weekly (total of 8 doses) |
| Weeks 9 to 24a | every two weeks (total of 8 doses) |
| Week 25 onwards until disease progression or a maximum of 2 yearsb | every four weeks |
| a First dose of the every-2-week dosing schedule is given at Week 9 b First dose of the every-4-week dosing schedule is given at Week 25 |
|
When DARZALEX FASPRO is administered as part of a combination therapy, see Clinical Studies and the prescribing information for dosage recommendations for the other drugs.
If a dose of DARZALEX FASPRO is missed, administer the dose as soon as possible and adjust the dosing schedule to maintain the dosing interval.
Administer the following pre-medications 1-3 hours before each dose of DARZALEX FASPRO:
Monotherapy
Administer methylprednisolone 100 mg (or equivalent) orally or intravenously. Consider reducing the dose of methylprednisolone to 60 mg (or equivalent) following the second dose of DARZALEX FASPRO.
In Combination
Administer dexamethasone 20 mg (or equivalent) orally or intravenously prior to every DARZALEX FASPRO administration.
When dexamethasone is the background regimen-specific corticosteroid, the dexamethasone dose that is part of the background regimen will serve as pre-medication on DARZALEX FASPRO administration days [see Clinical Studies].
Do not administer background regimen-specific corticosteroids (e.g. prednisone) on DARZALEX FASPRO administration days when patients have received dexamethasone (or equivalent) as a pre-medication.
Administer the following post-medications:
Monotherapy
Administer methylprednisolone 20 mg (or an equivalent dose of an intermediate- or long-acting corticosteroid) orally for 2 days starting the day after the administration of DARZALEX FASPRO.
In Combination
Consider administering oral methylprednisolone at a dose of less than or equal to 20 mg (or an equivalent dose of an intermediate- or long-acting corticosteroid) on the day after administration of DARZALEX FASPRO.
If a background regimen-specific corticosteroid (e.g., dexamethasone, prednisone) is administered the day after the administration of DARZALEX FASPRO, additional corticosteroids may not be needed [see Clinical Studies].
If the patient does not experience a major systemic administration-related reaction after the first 3 doses of DARZALEX FASPRO, consider discontinuing the administration of corticosteroids (excluding any background regimen-specific corticosteroid).
For patients with a history of chronic obstructive pulmonary disease, consider prescribing short and long-acting bronchodilators and inhaled corticosteroids. Following the first 4 doses of DARZALEX FASPRO, consider discontinuing these additional post-medications, if the patient does not experience a major systemic administration-related reaction.
Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 1 week after starting DARZALEX FASPRO and continue for 3 months following the end of treatment [see ADVERSE REACTIONS].
No dose reductions of DARZALEX FASPRO are recommended. Consider withholding DARZALEX FASPRO to allow recovery of blood cell counts in the event of myelosuppression [see WARNINGS AND PRECAUTIONS].
DARZALEX FASPRO should be administered by a healthcare provider.
To prevent medication errors, check the vial labels to ensure that the drug being prepared and administered is DARZALEX FASPRO for subcutaneous use. Do not administer DARZALEX FASPRO intravenously.
DARZALEX FASPRO is ready to use.
Injection: 1,800 mg daratumumab and 30,000 units hyaluronidase per 15 mL (120 mg and 2,000 units/mL) colorless to yellow and clear to opalescent solution in a single-dose vial.
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) injection is a sterile, preservative-free, colorless to yellow, and clear to opalescent solution for subcutaneous use supplied as individually packaged single-dose vials providing 1,800 mg of daratumumab and 30,000 units of hyaluronidase per 15 mL (NDC 57894-503-01).
Store DARZALEX FASPRO vials in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
Do not freeze or shake.
Manufactured by: Janssen Biotech, Inc. Horsham, PA 19044, USA. Revised: Jul 2024
The following clinically significant adverse reactions are described elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety of DARZALEX FASPRO in combination with bortezomib, lenalidomide and dexamethasone (n=351) from the start of induction to the end of consolidation compared to bortezomib, lenalidomide and dexamethasone (VRd) (n=347) was evaluated in PERSEUS [see Clinical Studies]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8 and once every 2 weeks from weeks 9 to 16 during induction in combination with VRd or VRd alone. After week 16, patients underwent stem cell mobilization, high dose chemotherapy, and ASCT. Within 12 weeks of ASCT, and when engraftment was complete, patients received DARZALEX FASPRO once every 2 weeks from weeks 1 to 8 during consolidation in combination with VRd or VRd alone.
The median duration of treatment for induction and consolidation was 9.9 months (0.5 to 18.5 months) for DARZALEX FASPRO-VRd.
Serious adverse reactions occurred in 37% of patients who received DARZALEX FASPRO-VRd. The most frequent serious adverse reaction in >5% of patients who received DARZALEX FASPRO-VRd was pneumonia (6%). Fatal adverse reactions occurred in 1.7% of patients who received DARZALEX FASPRO-VRd.
Permanent treatment discontinuation due to an adverse reaction occurred in 2% of patients who received DARZALEX FASPRO-VRd. An adverse reaction which resulted in permanent discontinuation of DARZALEX FASPRO-VRd in more than 1 patient included sepsis.
The most common adverse reactions (≥20%) were peripheral neuropathy, fatigue, edema, pyrexia, upper respiratory infection, constipation, diarrhea, musculoskeletal pain, insomnia, and rash.
Table 7 summarizes the adverse reactions in patients who received DARZALEX FASPRO in PERSEUS.
Table 7: Adverse Reactions (≥10%) in Patients with Newly Diagnosed Multiple Myeloma Eligible for ASCT Who Received DARZALEX FASPRO-VRd through the End of Consolidation in PERSEUS
| Adverse Reaction | DARZALEX FASPRO-VRd (N=351) |
VRd (N=347) |
||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Nervous system disorders | ||||
| Peripheral neuropathya | 52 | 5 | 54 | 4 |
| Paraesthesia | 11 | <1# | 11 | <1# |
| General disorders and administration site conditions | ||||
| Fatigueb | 35 | 3# | 37 | 5# |
| Edemab | 22 | 1 | 21 | 1# |
| Pyrexia | 21 | 2# | 22 | 3# |
| Infections | ||||
| Upper respiratory tract infectionc | 32 | 1# | 26 | 2# |
| Pneumoniad | 14 | 9 | 10 | 6@ |
| Gastrointestinal disorders | ||||
| Constipation | 31 | 2# | 30 | 2# |
| Diarrhea | 23 | 3# | 25 | 5# |
| Nausea | 16 | 1# | 12 | 1# |
| Abdominal painb | 11 | 0 | 12 | 0 |
| Musculoskeletal and connective tissue disorders | ||||
| Musculoskeletal painb | 26 | 1# | 23 | 1# |
| Muscle spasm | 12 | 0 | 9 | <1# |
| Psychiatric disorders | ||||
| Insomnia | 26 | 2# | 16 | 2# |
| Skin and subcutaneous tissue disorders | ||||
| Rashb | 25 | 3# | 31 | 5 |
| Hepatobiliary disorders | ||||
| Hepatotoxicitye | 16 | 6# | 16 | 5 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Coughb | 12 | <1# | 8 | 0 |
| Key: VRd=bortezomib-lenalidomide-dexamethasone a Peripheral neuropathy includes neuropathy peripheral, peripheral motor neuropathy, peripheral sensorimotor neuropathy, and peripheral sensory neuropathy. b Includes other related terms. c Upper respiratory tract infection includes fungal pharyngitis, h1n1 influenza, influenza, influenza like illness, laryngitis, nasopharyngitis, oral candidiasis, oropharyngeal candidiasis, parainfluenzae virus infection, pharyngitis, respiratory moniliasis, respiratory syncytial virus infection, respiratory tract infection, respiratory tract infection viral, rhinitis, rhinovirus infection, sinusitis, tonsillitis, upper respiratory tract infection, viral tonsillitis, and viral upper respiratory tract infection. d Pneumonia includes bronchopulmonary aspergillosis, lower respiratory tract infection, pneumocystis jirovecii pneumonia, pneumonia, pneumonia bacterial, pneumonia cytomegaloviral, pneumonia influenzal, pneumonia klebsiella, pneumonia legionella, and pneumonia streptococcal. e Hepatotoxicity includes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic cytolysis, hepatic failure, hepatic function abnormal, hepatoxicity, hyperbilirubinemia, hypertransaminasemia, and liver disorder # Only Grade 3 adverse reactions occurred. @ Fatal adverse reactions included Pneumonia: n=1 (0.3%) in the VRd arm. |
||||
Clinically relevant adverse reactions in <10% of patients who received DARZALEX FASPRO with bortezomib, lenalidomide and dexamethasone include:
Table 8 summarizes the laboratory abnormalities in patients who received DARZALEX FASPRO in PERSEUS.
Table 8: Select Laboratory Abnormalities (≥30%) That Worsened from Baseline in Patients with Newly Diagnosed Multiple Myeloma Eligible for ASCT Who Received DARZALEX FASPRO-VRd through the End of Consolidation in PERSEUS
| Laboratory Abnormality | DARZALEX FASPRO-VRda | VRda | ||
| All Grades (%) | Grade 3 or 4 (%) | All Grades (%) | Grade 3 or 4 (%) | |
| Hematology | ||||
| Decreased platelets | 89 | 34 | 78 | 25 |
| Decreased lymphocytes | 87 | 69 | 69 | 43 |
| Decreased leukocytes | 78 | 47 | 56 | 22 |
| Decreased neutrophils | 67 | 52 | 47 | 34 |
| Decreased hemoglobin | 39 | 7 | 43 | 6 |
| Chemistry | ||||
| Increased alanine aminotransferase (ALT) | 52 | 7 | 48 | 5 |
| Decreased sodium | 40 | 5 | 25 | 5 |
| Increased alkaline phosphatase | 39 | 0 | 36 | 1 |
| Decreased potassium | 30 | 6 | 24 | 3 |
| Key: VRd=bortezomib-lenalidomide-dexamethasone a Denominator is based on number of subjects with a baseline and post-baseline laboratory value for each laboratory test: N=351 for DARZALEX FASPRO-VRd and N=346 for VRd. |
||||
The safety of DARZALEX FASPRO with bortezomib, melphalan and prednisone was evaluated in a single-arm cohort of PLEIADES [see Clinical Studies]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 6, once every 3 weeks from weeks 7 to 54 and once every 4 weeks starting with week 55 until disease progression or unacceptable toxicity (N=67) in combination with bortezomib, melphalan and prednisone. Among these patients, 93% were exposed for 6 months or longer and 19% were exposed for greater than one year.
Serious adverse reactions occurred in 39% of patients who received DARZALEX FASPRO. Serious adverse reactions in >5% of patients included pneumonia and pyrexia. Fatal adverse reactions occurred in 3% of patients.
Permanent discontinuation of DARZALEX FASPRO due to an adverse reaction occurred in 4.5% of patients. The adverse reaction resulting in permanent discontinuation of DARZALEX FASPRO in more than 1 patient was neutropenic sepsis.
Dosage interruptions (defined as dose delays or skipped doses) due to an adverse reaction occurred in 51% of patients who received DARZALEX FASPRO. Adverse reactions requiring dosage interruptions in >5% of patients included thrombocytopenia, neutropenia, anemia, and pneumonia.
The most common adverse reactions (≥20%) were upper respiratory tract infection, constipation, nausea, fatigue, pyrexia, peripheral sensory neuropathy, diarrhea, cough, insomnia, vomiting, and back pain.
Table 9 summarizes the adverse reactions in patients who received DARZALEX FASPRO in PLEIADES.
Table 9: Adverse Reactions (≥10%) in Patients Who Received DARZALEX FASPRO with Bortezomib, Melphalan and Prednisone (DARZALEX FASPRO-VMP) in PLEIADES
| Adverse Reaction | DARZALEX FASPRO with Bortezomib, Melphalan and Prednisone (N=67) | |
| All Grades (%) | Grades ≥3 (%) | |
| Infections | ||
| Upper respiratory tract infectiona | 39 | 0 |
| Bronchitis | 16 | 0 |
| Pneumoniab | 15 | 7# |
| Gastrointestinal disorders | ||
| Constipation | 37 | 0 |
| Nausea | 36 | 0 |
| Diarrhea | 33 | 3# |
| Vomiting | 21 | 0 |
| Abdominal painc | 13 | 0 |
| General disorders and administration site conditions | ||
| Fatigued | 36 | 3 |
| Pyrexia | 34 | 0 |
| Edema peripherale | 13 | 1# |
| Nervous system disorders | ||
| Peripheral sensory neuropathy | 34 | 1# |
| Dizziness | 10 | 0 |
| Respiratory, thoracic and mediastinal disorders | ||
| Coughf | 24 | 0 |
| Psychiatric disorders | ||
| Insomnia | 22 | 3# |
| Musculoskeletal and connective tissue disorders | ||
| Back pain | 21 | 3# |
| Musculoskeletal chest pain | 12 | 0 |
| Metabolism and nutrition disorders | ||
| Decreased appetite | 15 | 1# |
| Skin and subcutaneous tissue disorders | ||
| Rash | 13 | 0 |
| Pruritus | 12 | 0 |
| Vascular disorders | ||
| Hypertension | 13 | 6# |
| Hypotension | 10 | 3# |
| a Upper respiratory tract infection includes nasopharyngitis, respiratory syncytial virus infection, respiratory tract infection, rhinitis, tonsillitis, upper respiratory tract infection, and viral pharyngitis. b Pneumonia includes lower respiratory tract infection, lung infection, pneumocystis jirovecii pneumonia, pneumonia, and pneumonia bacterial. c Abdominal pain includes abdominal pain, and abdominal pain upper. d Fatigue includes asthenia, and fatigue. e Edema peripheral includes edema, edema peripheral, and peripheral swelling. f Cough includes cough, and productive cough. # Only Grade 3 adverse reactions occurred. |
||
Clinically relevant adverse reactions in <10% of patients who received DARZALEX FASPRO with bortezomib, melphalan and prednisone included:
Table 10 summarizes the laboratory abnormalities in patients who received DARZALEX FASPRO in PLEIADES.
Table 10: Select Hematology Laboratory Abnormalities Worsening from Baseline in Patients Who Received DARZALEX FASPRO with Bortezomib, Melphalan and Prednisone (DARZALEX FASPRO-VMP) in PLEIADES
| Laboratory Abnormality | DARZALEX FASPRO with Bortezomib, Melphalan and Prednisonea | |
| All Grades (%) | Grades 3-4 (%) | |
| Decreased leukocytes | 96 | 52 |
| Decreased lymphocytes | 93 | 84 |
| Decreased platelets | 93 | 42 |
| Decreased neutrophils | 88 | 49 |
| Decreased hemoglobin | 48 | 19 |
| a Denominator is based on the safety population treated with DARZALEX FASPRO-VMP (N=67). | ||
The safety of DARZALEX FASPRO with lenalidomide and dexamethasone was evaluated in a single-arm cohort of PLEIADES [see Clinical Studies]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity (N=65) in combination with lenalidomide and dexamethasone. Among these patients, 92% were exposed for 6 months or longer and 20% were exposed for greater than one year.
Serious adverse reactions occurred in 48% of patients who received DARZALEX FASPRO. Serious adverse reactions in >5% of patients included pneumonia, influenza and diarrhea. Fatal adverse reactions occurred in 3.1% of patients.
Permanent discontinuation of DARZALEX FASPRO due to an adverse reaction occurred in 11% of patients who received DARZALEX FASPRO. Adverse reactions resulting in permanent discontinuation of DARZALEX FASPRO in more than 1 patient were pneumonia and anemia.
Dosage interruptions due to an adverse reaction occurred in 63% of patients who received DARZALEX FASPRO. Adverse reactions requiring dosage interruptions in >5% of patients included neutropenia, pneumonia, upper respiratory tract infection, influenza, dyspnea, and blood creatinine increased.
The most common adverse reactions (≥20%) were fatigue, diarrhea, upper respiratory tract infection, muscle spasms, constipation, pyrexia, pneumonia, and dyspnea.
Table 11 summarizes the adverse reactions in patients who received DARZALEX FASPRO in PLEIADES.
Table 11: Adverse Reactions (≥10%) in Patients Who Received DARZALEX FASPRO with Lenalidomide and Dexamethasone (DARZALEX FASPRO-Rd) in PLEIADES
| Adverse Reaction | DARZALEX FASPRO with Lenalidomide and Dexamethasone (N=65) |
|
| All Grades (%) | Grades ≥3 (%) | |
| General disorders and administration site conditions | ||
| Fatiguea | 52 | 5# |
| Pyrexia | 23 | 2# |
| Edema peripheral | 18 | 3# |
| Gastrointestinal disorders | ||
| Diarrhea | 45 | 5# |
| Constipation | 26 | 2# |
| Nausea | 12 | 0 |
| Vomiting | 11 | 0 |
| Infections | ||
| Upper respiratory tract infectionb | 43 | 3# |
| Pneumoniac | 23 | 17 |
| Bronchitisd | 14 | 2# |
| Urinary tract infection | 11 | 0 |
| Musculoskeletal and connective tissue disorders | ||
| Muscle spasms | 31 | 2# |
| Back pain | 14 | 0 |
| Respiratory, thoracic and mediastinal disorders | ||
| Dyspneae | 22 | 3 |
| Coughf | 14 | 0 |
| Nervous system disorders | ||
| Peripheral sensory neuropathy | 17 | 2# |
| Psychiatric disorders | ||
| Insomnia | 17 | 5# |
| Metabolism and nutrition disorders | ||
| Hyperglycemia | 12 | 9# |
| Hypocalcemia | 11 | 0 |
| a Fatigue includes asthenia, and fatigue. b Upper respiratory tract infection includes nasopharyngitis, pharyngitis, respiratory tract infection viral, rhinitis, sinusitis, upper respiratory tract infection, and upper respiratory tract infection bacterial. c Pneumonia includes lower respiratory tract infection, lung infection, and pneumonia. d Bronchitis includes bronchitis, and bronchitis viral. e Dyspnea includes dyspnea, and dyspnea exertional. f Cough includes cough, and productive cough. # Only Grade 3 adverse reactions occurred. |
||
Clinically relevant adverse reactions in <10% of patients who received DARZALEX FASPRO with lenalidomide and dexamethasone included:
Table 12 summarizes the laboratory abnormalities in patients who received DARZALEX FASPRO in PLEIADES.
Table 12: Select Hematology Laboratory Abnormalities Worsening from Baseline in Patients Who Received DARZALEX FASPRO with Lenalidomide and Dexamethasone (DARZALEX FASPRO-Rd) in PLEIADES
| Laboratory Abnormality | DARZALEX FASPRO with Lenalidomide and Dexamethasonea | |
| All Grades (%) | Grades 3-4 (%) | |
| Decreased leukocytes | 94 | 34 |
| Decreased lymphocytes | 82 | 58 |
| Decreased platelets | 86 | 9 |
| Decreased neutrophils | 89 | 52 |
| Decreased hemoglobin | 45 | 8 |
| a Denominator is based on the safety population treated with DARZALEX FASPRO-Rd (N=65). | ||
The safety of DARZALEX FASPRO with pomalidomide and dexamethasone compared to pomalidomide and dexamethasone (Pd) in patients who had received at least one prior line of therapy with lenalidomide and a proteasome inhibitor (PI) was evaluated in APOLLO [see Clinical Studies]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity in combination with pomalidomide and dexamethasone (n=149) or pomalidomide and dexamethasone (n=150). Among patients receiving DARZALEX FASPRO-Pd, 71% were exposed for 6 months or longer and 50% were exposed for greater than one year.
Serious adverse reactions occurred in 50% of patients who received DARZALEX FASPRO-Pd. The most frequent serious adverse reactions in >5% of patients who received DARZALEX FASPRO-Pd were pneumonia (15%) and lower respiratory tract infection (12%). Fatal adverse reactions occurred in 7% of patients who received DARZALEX FASPRO-Pd.
Permanent treatment discontinuation due to an adverse reaction occurred in 2% of patients who received DARZALEX FASPRO-Pd.
The most common adverse reactions (≥20%) were fatigue, pneumonia, upper respiratory tract infection, and diarrhea.
Table 13 summarizes the adverse reactions in patients who received DARZALEX FASPRO in APOLLO.
Table 13: Adverse Reactions Reported in ≥10% of Patients and With at Least a 5% Greater Frequency in the DARZALEX FASPRO-Pd Arm in APOLLO
| Adverse Reaction | DARZALEX FASPRO-Pd (N=149) |
Pd (N=150) |
||
| All Grades (%) | Grades ≥3 (%) | All Grades (%) | Grades ≥3 (%) | |
| General disorders and administration site conditions | ||||
| Fatiguea | 46 | 13 | 39 | 5# |
| Pyrexia | 19 | 0 | 14 | 0 |
| Edema peripheralb | 15 | 0 | 9 | 0 |
| Infections | ||||
| Pneumoniac | 38 | 23@ | 27 | 17@ |
| Upper respiratory infectiond | 36 | 1# | 22 | 2# |
| Gastrointestinal disorders | ||||
| Diarrhea | 22 | 5# | 14 | 1# |
| Respiratory, thoracic and mediastinal disorders | ||||
| Coughe | 13 | 0 | 8 | 0 |
| Key: Pd=pomalidomide-dexamethasone a Fatigue includes asthenia, and fatigue. b Edema peripheral includes edema, edema peripheral and peripheral swelling. c Pneumonia includes atypical pneumonia, lower respiratory tract infection, pneumonia, pneumonia aspiration, pneumonia bacterial, and pneumonia respiratory syncytial viral. d Upper respiratory tract infection includes nasopharyngitis, pharyngitis, respiratory syncytial virus infection, respiratory tract infection, respiratory tract infection viral, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, and viral upper respiratory tract infection. e Cough includes cough, and productive cough. # Only Grade 3 adverse reactions occurred. @ Grade 5 adverse reactions occurred, n=3 (2.0%) in the DARZALEX FASPRO-Pd arm and n=2 (1.3%) in the Pd arm. |
||||
Clinically relevant adverse reactions in <10% of patients who received DARZALEX FASPRO with pomalidomide and dexamethasone include:
Table 14 summarizes the laboratory abnormalities in patients who received DARZALEX FASPRO in APOLLO.
Table 14: Select Hematology Laboratory Abnormalities Worsening from Baseline in Patients Who Received DARZALEX FASPRO-Pd or Pd in APOLLO
| Laboratory Abnormality | DARZALEX FASPRO-Pda | Pda | ||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Decreased neutrophils | 97 | 84 | 84 | 63 |
| Decreased leukocytes | 95 | 64 | 82 | 40 |
| Decreased lymphocytes | 93 | 59 | 79 | 33 |
| Decreased platelets | 75 | 19 | 60 | 19 |
| Decreased hemoglobin | 51 | 16 | 57 | 15 |
| Key: Pd=pomalidomide-dexamethasone a Denominator is based on number of subjects with a baseline and post-baseline laboratory value for each laboratory test: N=148 for DARZALEX FASPRO-Pd and N=149 for Pd. |
||||
The safety of DARZALEX FASPRO with carfilzomib and dexamethasone was evaluated in a single-arm cohort of PLEIADES [see Clinical Studies]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from Weeks 1 to 8, once every 2 weeks from Weeks 9 to 24 and once every 4 weeks starting with Week 25 until disease progression or unacceptable toxicity (N=66) in combination with carfilzomib and dexamethasone. Among these patients, 77% were exposed for 6 months or longer and 27% were exposed for greater than one year.
Serious adverse reactions occurred in 27% of patients who received DARZALEX FASPRO in combination with carfilzomib and dexamethasone. Fatal adverse reactions occurred in 3% of patients who received DARZALEX FASPRO in combination with carfilzomib and dexamethasone.
Permanent discontinuation of DARZALEX FASPRO due to an adverse reaction occurred in 6% of patients who received DARZALEX FASPRO.
Dosage interruptions due to an adverse reaction occurred in 46% of patients who received DARZALEX FASPRO.
The most common adverse reactions (≥20%) were upper respiratory tract infection, fatigue, insomnia, hypertension, diarrhea, cough, dyspnea, headache, pyrexia, nausea, and edema peripheral.
Table 15 summarizes the adverse reactions in patients who received DARZALEX FASPRO with carfilzomib and dexamethasone (DARZALEX FASPRO-Kd) in PLEIADES.
Table 15: Adverse Reactions (≥10%) in Patients Who Received DARZALEX FASPRO with Carfilzomib and Dexamethasone (DARZALEX FASPRO-Kd) in PLEIADES
| Adverse Reaction | DARZALEX FASPRO-Kd (N=66) |
|
| All Grades (%) | Grade ≥3 (%) | |
| Infections and infestations | ||
| Upper respiratory tract infectiona | 52 | 0 |
| Bronchitisb | 12 | 2# |
| General disorders and administration site conditions | ||
| Fatiguec | 39 | 2# |
| Pyrexia | 21 | 2# |
| Edema peripherald | 20 | 0 |
| Psychiatric disorders | ||
| Insomnia | 33 | 6# |
| Vascular disorders | ||
| Hypertensione | 32 | 21# |
| Gastrointestinal disorders | ||
| Diarrhea | 29 | 0 |
| Nausea | 21 | 0 |
| Vomiting | 15 | 0 |
| Respiratory, thoracic and mediastinal disorders | ||
| Coughf | 24 | 0 |
| Dyspneag | 23 | 2# |
| Nervous system disorders | ||
| Headache | 23 | 0 |
| Peripheral sensory neuropathy | 11 | 0 |
| Musculoskeletal and connective tissue disorders | ||
| Back pain | 17 | 2# |
| Musculoskeletal chest pain | 11 | 0 |
| a Upper respiratory tract infection includes nasopharyngitis, pharyngitis, respiratory tract infection, respiratory tract infection viral, rhinitis, sinusitis, tonsillitis, upper respiratory tract infection, viral pharyngitis, and viral upper respiratory tract infection. b Bronchitis includes bronchitis, and bronchitis viral. c Fatigue includes asthenia, and fatigue. d Edema peripheral includes generalized edema, edema peripheral, and peripheral swelling. e Hypertension includes blood pressure increased, and hypertension. f Cough includes cough, and productive cough. g Dyspnea includes dyspnea, and dyspnea exertional. # Only Grade 3 adverse reactions occurred. |
||
Clinically relevant adverse reactions in <10% of patients who received DARZALEX FASPRO with carfilzomib and dexamethasone include:
Table 16 summarizes the laboratory abnormalities in patients who received DARZALEX FASPRO with carfilzomib and dexamethasone in PLEIADES.
Table 16: Select Laboratory Abnormalities (≥30%) Worsening from Baseline in Patients Who Received DARZALEX FASPRO-Kd in PLEIADES
| Laboratory Abnormality | DARZALEX FASPRO-Kda | |
| All Grades (%) | Grades 3-4 (%) | |
| Decreased platelets | 88 | 18 |
| Decreased lymphocytes | 83 | 50 |
| Decreased leukocytes | 68 | 18 |
| Decreased neutrophils | 55 | 15 |
| Decreased hemoglobin | 47 | 6 |
| Decreased corrected calcium | 45 | 2 |
| Increased alanine aminotransferase (ALT) | 35 | 5 |
| a Denominator is based on the safety population treated with DARZALEX FASPRO-Kd (N=66). | ||
The safety of DARZALEX FASPRO as monotherapy was evaluated in COLUMBA [see Clinical Trials]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously or daratumumab 16 mg/kg administered intravenously; each administered once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity. Among patients receiving DARZALEX FASPRO, 37% were exposed for 6 months or longer and 1% were exposed for greater than one year.
Serious adverse reactions occurred in 26% of patients who received DARZALEX FASPRO. Fatal adverse reactions occurred in 5% of patients. Fatal adverse reactions occurring in more than 1 patient were general physical health deterioration, septic shock, and respiratory failure.
Permanent discontinuation due to an adverse reaction occurred in 10% of patients who received DARZALEX FASPRO. Adverse reactions resulting in permanent discontinuation of DARZALEX FASPRO in more than 2 patients were thrombocytopenia and hypercalcemia.
Dosage interruptions due to an adverse reaction occurred in 26% of patients who received DARZALEX FASPRO. Adverse reactions requiring dosage interruption in >5% of patients included thrombocytopenia.
The most common adverse reaction (≥20%) was upper respiratory tract infection.
Table 17 summarizes the adverse reactions in COLUMBA.
Table 17: Adverse Reactions (≥10%) in Patients Who Received DARZALEX FASPRO or Intravenous Daratumumab in COLUMBA
| Adverse Reaction | DARZALEX FASPRO (N=260) |
Intravenous Daratumumab (N=258) |
||
| All Grades (%) | Grade ≥3 (%) | All Grades (%) | Grade ≥3 (%) | |
| Infections | ||||
| Upper respiratory tract infectiona | 24 | 1# | 22 | 1# |
| Pneumoniab | 8 | 5 | 10 | 6@ |
| Gastrointestinal disorders | ||||
| Diarrhea | 15 | 1# | 11 | 0.4# |
| Nausea | 8 | 0.4# | 11 | 0.4# |
| General disorders and administration site conditions | ||||
| Fatiguec | 15 | 1# | 16 | 2# |
| Infusion reactionsd | 13 | 2# | 34 | 5# |
| Pyrexia | 13 | 0 | 13 | 1# |
| Chills | 6 | 0.4# | 12 | 1# |
| Musculoskeletal and connective tissue disorders | ||||
| Back pain | 10 | 2# | 12 | 3# |
| Respiratory, thoracic and mediastinal disorders | ||||
| Coughe | 9 | 1# | 14 | 0 |
| Dyspneaf | 6 | 1# | 11 | 1# |
| a Upper respiratory tract infection includes acute sinusitis, nasopharyngitis, pharyngitis, respiratory syncytial virus infection, respiratory tract infection, rhinitis, rhinovirus infection, sinusitis, and upper respiratory tract infection. b Pneumonia includes lower respiratory tract infection, lung infection, pneumocystis jirovecii pneumonia, and pneumonia. c Fatigue includes asthenia, and fatigue. d Infusion reactions includes terms determined by investigators to be related to infusion. e Cough includes cough, and productive cough. f Dyspnea includes dyspnea, and dyspnea exertional. # Only Grade 3 adverse reactions occurred. @ Grade 5 adverse reactions occurred. |
||||
Clinically relevant adverse reactions in <10% of patients who received DARZALEX FASPRO included:
Table 18 summarizes the laboratory abnormalities in COLUMBA.
Table 18: Select Hematology Laboratory Abnormalities Worsening from Baseline in Patients Receiving DARZALEX FASPRO or Intravenous Daratumumab in COLUMBA
| Laboratory Abnormality | DARZALEX FASPROa | Intravenous Daratumumaba | ||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Decreased leukocytes | 65 | 19 | 57 | 14 |
| Decreased lymphocytes | 59 | 36 | 56 | 36 |
| Decreased neutrophils | 55 | 19 | 43 | 11 |
| Decreased platelets | 43 | 16 | 45 | 14 |
| Decreased hemoglobin | 42 | 14 | 39 | 16 |
| a Denominator is based on the safety population treated with DARZALEX FASPRO (N=260) and Intravenous Daratumumab (N=258). | ||||
The safety of DARZALEX FASPRO with bortezomib, cyclophosphamide and dexamethasone (DARZALEX FASPRO-VCd) was evaluated in ANDROMEDA [see Clinical Studies]. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity or a maximum of 2 years. Among patients who received DARZALEX FASPRO-VCd, 74% were exposed for 6 months or longer and 32% were exposed for greater than one year.
Serious adverse reactions occurred in 43% of patients who received DARZALEX FASPRO in combination with VCd. Serious adverse reactions that occurred in at least 5% of patients in the DARZALEX FASPRO-VCd arm were pneumonia (9%), cardiac failure (8%), and sepsis (5%). Fatal adverse reactions occurred in 11% of patients. Fatal adverse reactions that occurred in more than one patient included cardiac arrest (4%), sudden death (3%), cardiac failure (3%), and sepsis (1%).
Permanent discontinuation of DARZALEX FASPRO due to an adverse reaction occurred in 5% of patients. Adverse reactions resulting in permanent discontinuation of DARZALEX FASPRO in more than one patient were pneumonia, sepsis, and cardiac failure.
Dosage interruptions (defined as dose delays or skipped doses) due to an adverse reaction occurred in 36% of patients who received DARZALEX FASPRO. Adverse reactions which required a dosage interruption in ≥3% of patients included upper respiratory tract infection (9%), pneumonia (6%), cardiac failure (4%), fatigue (3%), herpes zoster (3%), dyspnea (3%), and neutropenia (3%).
The most common adverse reactions (≥20%) were upper respiratory tract infection, diarrhea, peripheral edema, constipation, fatigue, peripheral sensory neuropathy, nausea, insomnia, dyspnea, and cough.
Table 19 below summarizes the adverse reactions in patients who received DARZALEX FASPRO in ANDROMEDA.
Table 19: Adverse Reactions (≥10%) in Patients with AL Amyloidosis Who Received DARZALEX FASPRO with Bortezomib, Cyclophosphamide and Dexamethasone (DARZALEX FASPRO-VCd) with a Difference Between Arms of >5% Compared to VCd in ANDROMEDA
| Adverse Reaction | DARZALEX FASPRO-VCd (N=193) |
VCd (N=188) |
||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Infections | ||||
| Upper respiratory tract infectiona | 40 | 1# | 21 | 1# |
| Pneumoniab | 15 | 10 | 9 | 5 |
| Gastrointestinal disorders | ||||
| Diarrhea | 36 | 6# | 30 | 4 |
| Constipation | 34 | 2# | 29 | 0 |
| Nervous system disorders | ||||
| Peripheral sensory neuropathy | 31 | 3# | 20 | 2# |
| Respiratory, thoracic and mediastinal disorders | ||||
| Dyspneac | 26 | 4 | 20 | 4# |
| Coughd | 20 | 1# | 11 | 0 |
| Musculoskeletal and connective tissue disorders | ||||
| Back pain | 12 | 2# | 6 | 0 |
| Arthralgia | 10 | 0 | 5 | 0 |
| Muscle spasms | 10 | 1# | 5 | 0 |
| Cardiac disorders | ||||
| Arrhythmiae | 11 | 4 | 5 | 2 |
| General disorders and administration site conditions | ||||
| Injection site reactionsf | 11 | 0 | 0 | 0 |
| # Only Grade 3 adverse reactions occurred. a Upper respiratory tract infection includes laryngitis, nasopharyngitis, pharyngitis, respiratory syncytial virus infection, respiratory tract infection, respiratory tract infection viral, rhinitis, rhinovirus infection, sinusitis, tonsillitis, tracheitis, upper respiratory tract infection, upper respiratory tract infection bacterial, and viral upper respiratory tract infection. b Pneumonia includes lower respiratory tract infection, pneumonia, pneumonia aspiration, and pneumonia pneumococcal. c Dyspnea includes dyspnea, and dyspnea exertional. d Cough includes cough, and productive cough. e Arrhythmia includes atrial flutter, atrial fibrillation, supraventricular tachycardia, bradycardia, arrhythmia, bradyarrhythmia, cardiac flutter, extrasystoles, supraventricular extrasystoles, ventricular arrhythmia, ventricular extrasystoles, atrial tachycardia, ventricular tachycardia f Injection site reactions includes terms determined by investigators to be related to daratumumab injection. |
||||
Clinically relevant adverse reactions not included in Table 19 and occurred in patients who received DARZALEX FASPRO with bortezomib, cyclophosphamide and dexamethasone included:
aCardiac failure includes cardiac dysfunction, cardiac failure, cardiac failure congestive, cardiovascular insufficiency, diastolic dysfunction, pulmonary edema, and left ventricular dysfunction occurred in 11% of patients.
Table 20 summarizes the laboratory abnormalities in patients who received DARZALEX FASPRO in ANDROMEDA.
Table 20: Select Hematology Laboratory Abnormalities Worsening from Baseline in Patients Who Received DARZALEX FASPRO with Bortezomib, Cyclophosphamide and Dexamethasone (DARZALEX FASPRO-VCd) in ANDROMEDA
| Laboratory Abnormality | DARZALEX FASPRO-VCd | VCd | ||
| All Grades (%) | Grades 3-4 (%) | All Grades (%) | Grades 3-4 (%) | |
| Decreased lymphocytes | 81 | 54 | 71 | 46 |
| Decreased hemoglobin | 66 | 6 | 70 | 6 |
| Decreased leukocytes | 60 | 7 | 46 | 4 |
| Decreased platelets | 46 | 3 | 40 | 4 |
| Decreased neutrophils | 30 | 6 | 18 | 4 |
| Denominator is based on the number of patients with a baseline and post-baseline laboratory value for each laboratory test, N=188 for DARZALEX FASPRO-VCd and N=186 for VCd. | ||||
Among patients who received DARZALEX FASPRO in combination with VCd, 72% of patients had baseline cardiac involvement with Mayo Cardiac Stage I (3%), Stage II (46%) and Stage III (51%). Serious cardiac disorders occurred in 16% of patients (8% of patients with Mayo Cardiac Stage I and II and 28% of patients with Stage III). Serious cardiac disorders in >2% of patients included cardiac failure (8%), cardiac arrest (4%) and arrhythmia (4%). Fatal cardiac disorders occurred in 10% of patients (5% of patients with Mayo Cardiac Stage I and II and 19% of patients with Stage III) who received DARZALEX FASPRO in combination with VCd. Fatal cardiac disorders that occurred in more than one patient in the DARZALEX FASPRO-VCd arm included cardiac arrest (4%), sudden death (3%), and cardiac failure (3%).
The following adverse reactions have been identified with post-approval use of daratumumab. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Immune System: Anaphylactic reaction, Systemic administration reactions (including death)
Gastrointestinal: Pancreatitis
Infections: Cytomegalovirus, Listeriosis
Daratumumab binds to CD38 on RBCs and interferes with compatibility testing, including antibody screening and cross matching. Daratumumab interference mitigation methods include treating reagent RBCs with dithiothreitol (DTT) to disrupt daratumumab binding [see REFERENCES] or genotyping. Since the Kell blood group system is also sensitive to DTT treatment, supply K-negative units after ruling out or identifying alloantibodies using DTT-treated RBCs.
If an emergency transfusion is required, administer non-cross-matched ABO/RhD-compatible RBCs per local blood bank practices.
Daratumumab may be detected on serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for monitoring disease monoclonal immunoglobulins (M protein). False positive SPE and IFE assay results may occur for patients with IgG kappa myeloma protein impacting initial assessment of complete responses by International Myeloma Working Group (IMWG) criteria. In DARZALEX FASPRO-treated patients with persistent very good partial response, where daratumumab interference is suspected, consider using a FDA-approved daratumumab-specific IFE assay to distinguish daratumumab from any remaining endogenous M protein in the patient’s serum, to facilitate determination of a complete response.
REFERENCES
1. Chapuy, CI, RT Nicholson, MD Aguad, et al., 2015, Resolving the daratumumab interference with blood compatibility testing, Transfusion, 55:1545-1554 (accessible at https://onlinelibrary.wiley.com/doi/10.1111/trf.13069/epdf).
Included as part of the "PRECAUTIONS" Section
Both systemic administration-related reactions, including severe or life-threatening reactions, and local injection-site reactions can occur with DARZALEX FASPRO. Fatal reactions have been reported with daratumumab-containing products, including DARZALEX FASPRO [see ADVERSE REACTIONS].
In a pooled safety population of 898 patients with multiple myeloma (N=705) or light chain (AL) amyloidosis (N=193) who received DARZALEX FASPRO as monotherapy or as part of a combination therapy, 9% of patients experienced a systemic administration-related reaction (Grade 2: 3.2%, Grade 3: 1%). Systemic administration-related reactions occurred in 8% of patients with the first injection, 0.3% with the second injection, and cumulatively 1% with subsequent injections. The median time to onset was 3.2 hours (range: 4 minutes to 3.5 days). Of the 140 systemic administration-related reactions that occurred in 77 patients, 121 (86%) occurred on the day of DARZALEX FASPRO administration. Delayed systemic administration-related reactions have occurred in 1% of the patients.
Severe reactions include hypoxia, dyspnea, hypertension, and tachycardia, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma. Other signs and symptoms of systemic administration-related reactions may include respiratory symptoms, such as bronchospasm, nasal congestion, cough, throat irritation, allergic rhinitis, and wheezing, as well as anaphylactic reaction, pyrexia, chest pain, pruritus, chills, vomiting, nausea, hypotension, and blurred vision.
Pre-medicate patients with histamine-1 receptor antagonist, acetaminophen and corticosteroids [see DOSAGE AND ADMINISTRATION]. Monitor patients for systemic administration-related reactions, especially following the first and second injections. For anaphylactic reaction or life-threatening (Grade 4) administration-related reactions, immediately and permanently discontinue DARZALEX FASPRO. Consider administering corticosteroids and other medications after the administration of DARZALEX FASPRO depending on dosing regimen and medical history to minimize the risk of delayed (defined as occurring the day after administration) systemic administration-related reactions [see DOSAGE AND ADMINISTRATION].
Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with daratumumab-containing products. If ocular symptoms occur, interrupt DARZALEX FASPRO and seek immediate ophthalmologic evaluation prior to restarting DARZALEX FASPRO.
In this pooled safety population, injection-site reactions occurred in 8% of patients, including Grade 2 reactions in 0.7%. The most frequent (>1%) injection-site reaction was injection site erythema. These local reactions occurred a median of 5 minutes (range: 0 minutes to 6.5 days) after starting administration of DARZALEX FASPRO. Monitor for local reactions and consider symptomatic management.
Serious or fatal cardiac adverse reactions occurred in patients with light chain (AL) amyloidosis who received DARZALEX FASPRO in combination with bortezomib, cyclophosphamide and dexamethasone [see ADVERSE REACTIONS]. Serious cardiac disorders occurred in 16% and fatal cardiac disorders occurred in 10% of patients. Patients with NYHA Class IIIA or Mayo Stage IIIA disease may be at greater risk. Patients with NYHA Class IIIB or IV disease were not studied.
Monitor patients with cardiac involvement of light chain (AL) amyloidosis more frequently for cardiac adverse reactions and administer supportive care as appropriate.
Daratumumab may increase neutropenia induced by background therapy [see ADVERSE REACTIONS].
Monitor complete blood cell counts periodically during treatment according to manufacturer’s prescribing information for background therapies. Monitor patients with neutropenia for signs of infection. Consider withholding DARZALEX FASPRO until recovery of neutrophils. In lower body weight patients receiving DARZALEX FASPRO, higher rates of Grade 3-4 neutropenia were observed.
Daratumumab may increase thrombocytopenia induced by background therapy [see ADVERSE REACTIONS].
Monitor complete blood cell counts periodically during treatment according to manufacturer’s prescribing information for background therapies. Consider withholding DARZALEX FASPRO until recovery of platelets.
Based on the mechanism of action, DARZALEX FASPRO can cause fetal harm when administered to a pregnant woman. DARZALEX FASPRO may cause depletion of fetal immune cells and decreased bone density. Advise pregnant women of the potential risk to a fetus. Advise females with reproductive potential to use effective contraception during treatment with DARZALEX FASPRO and for 3 months after the last dose [see Use In Specific Populations].
The combination of DARZALEX FASPRO with lenalidomide, thalidomide or pomalidomide is contraindicated in pregnant women, because lenalidomide, thalidomide or pomalidomide may cause birth defects and death of the unborn child. Refer to the lenalidomide, thalidomide or pomalidomide prescribing information on use during pregnancy.
Daratumumab binds to CD38 on red blood cells (RBCs) and results in a positive Indirect Antiglobulin Test (Indirect Coombs test). Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab administration. Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient’s serum [see REFERENCES]. The determination of a patient’s ABO and Rh blood type are not impacted [see DRUG INTERACTIONS].
Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX FASPRO. Type and screen patients prior to starting DARZALEX FASPRO [see DOSAGE AND ADMINISTRATION].
Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both the serum protein electrophoresis (SPE) and immunofixation (IFE) assays used for the clinical monitoring of endogenous M-protein [see DRUG INTERACTIONS]. This interference can impact the determination of complete response and of disease progression in some DARZALEX FASPRO-treated patients with IgG kappa myeloma protein.
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Advise patients to seek immediate medical attention for any of the following signs and symptoms of systemic administration-related reactions: itchy, runny or blocked nose; chills, nausea, throat irritation, cough, headache, shortness of breath or difficulty breathing, and blurred vision [see WARNINGS AND PRECAUTIONS].
Advise patients to immediately contact their healthcare provider if they have signs or symptoms of cardiac adverse reactions [see WARNINGS AND PRECAUTIONS].
Advise patients to contact their healthcare provider if they have a fever [see WARNINGS AND PRECAUTIONS].
Advise patients to contact their healthcare provider if they have bruising or bleeding [see WARNINGS AND PRECAUTIONS].
Advise pregnant women of the potential hazard to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see WARNINGS AND PRECAUTIONS, Use In Specific Populations].
Advise females of reproductive potential to avoid becoming pregnant during treatment with DARZALEX FASPRO and for 3 months after the last dose [see Use In Specific Populations].
Advise patients that lenalidomide, thalidomide and pomalidomide have the potential to cause fetal harm and have specific requirements regarding contraception, pregnancy testing, blood and sperm donation, and transmission in sperm.
Lenalidomide, thalidomide and pomalidomide are only available through a REMS program [see Use In Specific Populations].
Advise patients to inform their healthcare provider, including personnel at blood transfusion centers, that they are taking DARZALEX FASPRO, in the event of a planned transfusion [see WARNINGS AND PRECAUTIONS].
Advise patients that DARZALEX FASPRO can affect the results of some tests used to determine complete response in some patients and additional tests may be needed to evaluate response [see WARNINGS AND PRECAUTIONS].
Advise patients to inform healthcare providers if they have ever had or might have a hepatitis B infection and that DARZALEX FASPRO could cause hepatitis B virus to become active again [see ADVERSE REACTIONS].
No carcinogenicity or genotoxicity studies have been conducted with daratumumab. No animal studies have been performed to evaluate the potential effects of daratumumab on reproduction or development, or to determine potential effects on fertility in males or females.
No carcinogenicity, genotoxicity, or fertility studies were conducted for recombinant human hyaluronidase. There were no effects on reproductive tissues and function and no systemic exposure of hyaluronidase in monkeys given 22,000 U/kg/week subcutaneously (12 times higher than the human dose) for 39 weeks. As hyaluronidase is a recombinant form of the endogenous human hyaluronidase, no carcinogenicity, mutagenesis, or effects on fertility are expected.
DARZALEX FASPRO can cause fetal harm when administered to a pregnant woman. The assessment of associated risks with daratumumab products is based on the mechanism of action and data from target antigen CD38 knockout animal models (see Data). There are no available data on the use of DARZALEX FASPRO in pregnant women to evaluate drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
The combination of DARZALEX FASPRO and lenalidomide, thalidomide or pomalidomide is contraindicated in pregnant women, because lenalidomide, thalidomide and pomalidomide may cause birth defects and death of the unborn child. Lenalidomide, thalidomide and pomalidomide are only available through a REMS program. Refer to the lenalidomide, thalidomide or pomalidomide prescribing information on use during pregnancy.
Fetal/Neonatal Adverse Reactions
Immunoglobulin G1 (IgG1) monoclonal antibodies are transferred across the placenta. Based on its mechanism of action, DARZALEX FASPRO may cause depletion of fetal CD38 positive immune cells and decreased bone density. Defer administering live vaccines to neonates and infants exposed to daratumumab in utero until a hematology evaluation is completed.
Animal Data
DARZALEX FASPRO for subcutaneous injection contains daratumumab and hyaluronidase. Mice that were genetically modified to eliminate all CD38 expression (CD38 knockout mice) had reduced bone density at birth that recovered by 5 months of age. Data from studies using CD38 knockout animal models also suggest the involvement of CD38 in the regulation of humoral immune responses (mice), feto-maternal immune tolerance (mice), and early embryonic development (frogs).
No systemic exposure of hyaluronidase was detected in monkeys given 22,000 U/kg subcutaneously (12 times higher than the human dose) and there were no effects on embryo-fetal development in pregnant mice given 330,000 U/kg hyaluronidase subcutaneously daily during organogenesis, which is 45 times higher than the human dose. There were no effects on pre- and post-natal development through sexual maturity in offspring of mice treated daily from implantation through lactation with 990,000 U/kg hyaluronidase subcutaneously, which is 134 times higher than the human doses.
There is no data on the presence of daratumumab and hyaluronidase in human milk, the effects on the breastfed child, or the effects on milk production. Maternal immunoglobulin G is known to be present in human milk. Published data suggest that antibodies in breast milk do not enter the neonatal and infant circulations in substantial amounts. Because of the potential for serious adverse reactions in the breastfed child when DARZALEX FASPRO is administered with lenalidomide, thalidomide or pomalidomide, advise women not to breastfeed during treatment with DARZALEX FASPRO. Refer to lenalidomide, thalidomide or pomalidomide prescribing information for additional information.
Animal Data
No systemic exposure of hyaluronidase was detected in monkeys given 22,000 U/kg subcutaneously (12 times higher than the human dose) and there were no effects on post-natal development through sexual maturity in offspring of mice treated daily during lactation with 990,000 U/kg hyaluronidase subcutaneously, which is 134 times higher than the human doses.
DARZALEX FASPRO can cause fetal harm when administered to a pregnant woman [see Pregnancy].
With the combination of DARZALEX FASPRO with lenalidomide, thalidomide or pomalidomide, refer to the lenalidomide, thalidomide or pomalidomide labeling for pregnancy testing requirements prior to initiating treatment in females of reproductive potential.
Advise females of reproductive potential to use effective contraception during treatment with DARZALEX FASPRO and for 3 months after the last dose. Additionally, refer to the lenalidomide, thalidomide or pomalidomide labeling for additional recommendations for contraception.
Safety and effectiveness of DARZALEX FASPRO in pediatric patients have not been established.
Of the 291 patients who received DARZALEX FASPRO as monotherapy for relapsed and refractory multiple myeloma, 37% were 65 to <75 years of age, and 19% were 75 years of age or older. No overall differences in effectiveness of DARZALEX FASPRO have been observed between patients ≥65 years of age and younger patients. Adverse reactions that occurred at a higher frequency (≥5% difference) in patients ≥65 years of age included upper respiratory tract infection, urinary tract infection, dizziness, cough, dyspnea, diarrhea, nausea, fatigue, and peripheral edema.
Serious adverse reactions that occurred at a higher frequency (≥2% difference) in patients ≥65 years of age included pneumonia.
Of the 214 patients who received DARZALEX FASPRO as combination therapy with pomalidomide and dexamethasone or DARZALEX FASPRO as combination therapy with lenalidomide and low-dose dexamethasone for relapsed and refractory multiple myeloma, 43% were 65 to <75 years of age, and 18% were 75 years of age or older. No overall differences in effectiveness were observed between patients ≥65 years (n=131) and <65 years (n=85). Adverse reactions occurring at a higher frequency (≥5% difference) in patients ≥65 years of age included fatigue, pyrexia, peripheral edema, urinary tract infection, diarrhea, constipation, vomiting, dyspnea, cough, and hyperglycemia. Serious adverse reactions occurring at a higher frequency (≥2% difference) in patients ≥65 years of age included neutropenia, thrombocytopenia, diarrhea, anemia, COVID-19, ischemic colitis, deep vein thrombosis, general physical health deterioration, pulmonary embolism, and urinary tract infection.
Of the 193 patients who received DARZALEX FASPRO as part of a combination therapy for light chain (AL) amyloidosis, 35% were 65 to <75 years of age, and 10% were 75 years of age or older. Clinical studies of DARZALEX FASPRO as part of a combination therapy for patients with light chain (AL) amyloidosis did not include sufficient numbers of patients aged 65 and older to determine whether effectiveness differs from that of younger patients. Adverse reactions that occurred at a higher frequency in patients ≥65 years of age were peripheral edema, asthenia, pneumonia and hypotension.
No clinically meaningful differences in the pharmacokinetics of daratumumab were observed in geriatric patients compared to younger adult patients [see CLINICAL PHARMACOLOGY].
No Information provided
DARZALEX FASPRO is contraindicated in patients with a history of severe hypersensitivity to daratumumab, hyaluronidase or any of the components of the formulation [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS].
CD38 is a transmembrane glycoprotein (48 kDa) expressed on the surface of hematopoietic cells, including clonal plasma cells in multiple myeloma and light chain (AL) amyloidosis, as well as other cell types. Surface CD38 has multiple functions, including receptor mediated adhesion, signaling, and modulation of cyclase and hydrolase activity. Daratumumab is an IgG1τ human monoclonal antibody (mAb) that binds to CD38 and inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity (CDC), antibody dependent cell mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP). A subset of myeloid derived suppressor cells (CD38+MDSCs), regulatory T cells (CD38+Tregs) and B cells (CD38+Bregs) are decreased by daratumumab.
Hyaluronan is a polysaccharide found in the extracellular matrix of the subcutaneous tissue. It is depolymerized by the naturally occurring enzyme hyaluronidase. Unlike the stable structural components of the interstitial matrix, hyaluronan has a half-life of approximately 0.5 days. Hyaluronidase increases permeability of the subcutaneous tissue by depolymerizing hyaluronan. In the doses administered, hyaluronidase in DARZALEX FASPRO acts locally. The effects of hyaluronidase are reversible and permeability of the subcutaneous tissue is restored within 24 to 48 hours.
NK cells express CD38 and are susceptible to daratumumab mediated cell lysis. Decreases in absolute counts and percentages of total NK cells (CD16+CD56+) and activated (CD16+CD56dim) NK cells in peripheral whole blood and bone marrow were observed with DARZALEX FASPRO treatment.
DARZALEX FASPRO as a large protein has a low likelihood of direct ion channel interactions. There is no evidence from non-clinical or clinical data to suggest that DARZALEX FASPRO has the potential to delay ventricular repolarization.
The exposure-response relationship and time course of pharmacodynamics of DARZALEX FASPRO have not been fully characterized.
Following the recommended dose of DARZALEX FASPRO 1,800 mg/30,000 units subcutaneously once weekly for 8 weeks, daratumumab peak concentration (Cmax) increased 4.8Âfold and area under the curve (AUC0-7 days) increased 5.4-fold from the 1st dose to the 8th dose as monotherapy. Maximum trough concentrations for DARZALEX FASPRO are typically observed at the end of the weekly dosing regimens for both monotherapy and combination therapies. The mean ± standard deviation (SD) maximum trough serum concentration (Ctrough) after the 8th dose was 593 ± 306 μg/mL when DARZALEX FASPRO was administered as monotherapy and 537 ± 277 μg/mL, 526 ± 226 μg/mL, 756 ± 276 μg/mL, and 526 ± 209 μg/mL when DARZALEX FASPRO was administered as combination with Pd, Rd, Kd, and VRd, respectively.
Table 21 lists the observed mean (±SD) maximum trough concentrations (Ctrough) after the 8th dose, simulated median (5th-95th percentiles) maximum Ctrough after the 8th dose, simulated median (5th-95th percentiles) Cmax after the 8th dose, and simulated median (5th-95th percentiles) area under the curve (AUC0-7day) after the 8th dose following DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously or daratumumab 16 mg/kg administered intravenously in patients with multiple myeloma or light chain (AL) amyloidosis. Daratumumab exposures were similar between patients treated with DARZALEX FASPRO 1,800 mg/30,000 units monotherapy and combination therapies.
Table 21: Daratumumab Exposure for Patients with Multiple Myeloma or Light Chain (AL) Amyloidosis
| Parameter | Intravenous Daratumumab 16 mg/kg Monotherapy in Patients with Multiple Myeloma | DARZALEX FASPRO 1,800 mg/30,000 units Monotherapy in Patients with Multiple Myeloma | DARZALEX FASPRO 1,800 mg/30,000 units in combination with VRd in Patients with Transplant Eligible Multiple Myeloma | DARZALEX FASPRO 1,800 mg/30,000 units in combination with VCd in Patients with Light Chain (AL) Amyloidosis |
| Observed mean ± SD max Ctrough after 8th dose (μg/mL) | 522 ± 226a | 593 ± 306a | 526 ± 209 | 597 ± 232 |
| Simulated median (5th-95th percentiles) max Ctrough after 8th dose (μg/mL) | 472 (144-809) |
563 (177-1063) |
651 (413-915) |
662 (315-1037) |
| Simulated median (5th-95th percentiles) Cmax after 8th dose (μg/mL) | 688 (369-1061) |
592 (234-1114) |
678 (431-958) |
729 (390-1105) |
| Simulated median (5th-95th percentiles) AUC0-7days after 8th dose (μg/mL•day) | 4019 (1740-6370) |
4017 (1515-7564) |
4637 (2941-6522) |
4855 (2562-7522) |
| a Geometric mean ratio between 1,800 mg SC and 16 mg/kg was 108% (90% CI: 96, 122) in patients with multiple myeloma | ||||
At the recommended dose of DARZALEX FASPRO 1,800 mg/30,000 units, the absolute bioavailability is 69%, with peak concentrations occurring around 3 days (Tmax) in patients with multiple myeloma. Peak concentrations occurred around 4 days in patients with light chain (AL) amyloidosis.
The estimated mean (coefficient of variation, CV) volume of distribution for the central compartment is 5.2 L (37%) and peripheral compartment was 3.8 L in patients with multiple myeloma. The estimated mean volume of distribution was 10.8 L (28%) in patients with light chain (AL) amyloidosis.
Daratumumab is cleared by parallel linear and nonlinear saturable target mediated clearances. The estimated mean (CV%) linear clearance of daratumumab is 119 mL/day (59%) in patients with multiple myeloma and is 210 mL/day (42%) in patients with light chain (AL) amyloidosis. The estimated mean (CV%) elimination half-life associated with linear clearance is 20 days (22%) in patients with multiple myeloma and 28 days (74%) in patients with light chain (AL) amyloidosis.
The following population characteristics have no clinically meaningful effect on the pharmacokinetics of daratumumab in patients administered DARZALEX FASPRO as monotherapy or as combination therapy: sex, age (33 to 92 years), renal impairment [Creatinine clearance (CLcr) 15 to 89 mL/min as determined by the Cockcroft-Gault formula], and mild hepatic impairment (total bilirubin 1 to 1.5 times ULN and AST>ULN). The effect of moderate and severe hepatic impairment on daratumumab pharmacokinetics is unknown.
Of 190 patients with light chain (AL) amyloidosis who received DARZALEX FASPRO and had a maximum Ctrough after the 8th dose, African-Americans (4%) had 24% higher daratumumab mean maximum Ctrough after the 8th dose compared to that of Whites (83%) and Asians (10%) had 16% higher mean maximum Ctrough after the 8th dose compared to that of Whites. The difference in exposure between that of Asians and Whites could be explained in part by differences in body size. The effect of African-American race on exposure and related safety and efficacy of daratumumab is unknown.
In patients with multiple myeloma who received DARZALEX FASPRO 1,800 mg/30,000 units as monotherapy, the mean maximum Ctrough after the 8th dose was 12% lower in the higher body weight (BW) group (>85 kg), while the mean maximum Ctrough after the 8th dose was 81% higher in the lower BW group (≤50 kg) compared to the corresponding BW groups in the intravenous daratumumab arm.
In patients with light chain (AL) amyloidosis who received DARZALEX FASPRO 1,800 mg/30,000 units in combination and had a maximum Ctrough after the 8th dose, the mean maximum Ctrough after the 8th dose was 22% lower in the higher BW group (>85 kg), while the mean maximum Ctrough was 37% higher in the lower BW group (≤50 kg) compared to the patients with body weight of 51-85 kg.
The observed incidence of anti-drug antibody (ADA, including neutralizing antibody) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of daratumumab or of other daratumumab products.
With the median DARZALEX FASPRO treatment ranging from 6.5 to 35.9 months across 7 clinical trials of patients with multiple myeloma and light chain (AL) amyloidosis treated with DARZALEX as monotherapy or as combination therapies, the incidence of anti-daratumumab antibody development was 0.6% (7/1,200) and 6 patients tested positive for neutralizing antibodies. Because of the low occurrence of anti-daratumumab antibodies, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of daratumumab products is unknown.
With the median DARZALEX FASPRO treatment ranging from 6.5 to 35.9 months across 7 clinical trials of patients with multiple myeloma and light chain (AL) amyloidosis treated with DARZALEX as monotherapy or as combination therapies, the incidence of anti-rHuPH20 antibody development was 8.9% (106/1,193) and 1 patient tested positive for neutralizing antibodies. There was no identified clinically significant effect of anti-rHuPH20 antibodies on pharmacokinetics, pharmacodynamics, safety, or effectiveness of daratumumab products.
The efficacy of DARZALEX FASPRO with bortezomib, lenalidomide and dexamethasone (DARZALEX FASPRO-VRd) during induction and consolidation was evaluated in PERSEUS (NCT03710603), an open-label, randomized, active-controlled trial in patients with newly diagnosed multiple myeloma eligible for ASCT. Enrollment was limited to patients 70 years of age and younger.
Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8 and once every 2 weeks from weeks 9 to 16 during induction. After week 16, patients underwent stem cell mobilization, high dose chemotherapy, and ASCT. Within 12 weeks of ASCT, and when engraftment was complete, patients received DARZALEX FASPRO once every 2 weeks from weeks 1 to 8 during consolidation. Bortezomib was administered by subcutaneous injection at a dose of 1.3 mg/m² body surface area twice weekly for two weeks (days 1, 4, 8, and 11) of each 28-day cycle for weeks 1-16 during induction and weeks 1-8 during consolidation. Lenalidomide was administered orally at 25 mg daily (days 1-21) during weeks 1Â16 during induction and weeks 1-8 during consolidation. Dexamethasone (oral or intravenous) was administered at 40 mg on Days 1-4 and Days 9-12 during weeks 1-16 during induction and weeks 1-8 during consolidation. On the days of DARZALEX FASPRO injection, the dexamethasone dose was administered orally or intravenously as a pre-injection medication. Following consolidation, patients received an investigational treatment regimen for maintenance that included DARZALEX FASPRO in combination with lenalidomide or lenalidomide alone. The trial was not designed to isolate the effect of DARZALEX FASPRO in the maintenance phase of treatment. The efficacy of DARZALEX FASPRO in combination with lenalidomide for maintenance has not been established.
The major efficacy outcome measure was progression-free survival (PFS) by independent review committee (IRC) based on IMWG response criteria.
A total of 709 patients were randomized: 355 to the DARZALEX FASPRO-VRd arm and 354 to the VRd arm. The median age was 60 years (range: 31 to 70); 59% were male, 92% were White, 1% were Black or African American, and 1% were Asian. Fifty-one percent had ISS Stage I, 34% had ISS Stage II, 15% had ISS Stage III disease. High-risk cytogenetics (presence of del(17p), t(4;14), t(14,16)) were present in 22% of patients.
PERSEUS demonstrated an improvement in PFS in the DARZALEX FASPRO-VRd arm as compared to the VRd arm; the median PFS had not been reached in either arm. Treatment with DARZALEX FASPRO-VRd resulted in a reduction in the risk of disease progression or death by 60% compared to VRd alone (HR [95% CI]: 0.40 [0.29, 0.57]; p-value < 0.0001).
Figure 1: Kaplan-Meier Curve of PFS in PERSEUS
 |
Additional efficacy results from PERSEUS are presented in Table 22.
Table 22: Efficacy Results through End of Consolidation from PERSEUS
| DARZALEX FASPRO-VRd (n=355) |
VRd (n=354) |
|
| Overall response (sCR+CR+VGPR+PR), n (%)a | 338 (95.2%) | 326 (92.1%) |
| Stringent complete response (sCR) | 67 (18.9%) | 46 (13.0%) |
| Complete response (CR) | 91 (25.6%) | 77 (21.8%) |
| Very good partial response (VGPR) | 165 (46.5%) | 168 (47.5%) |
| Partial response (PR) | 15 (4.2%) | 35 (9.9%) |
| CR or better (sCR+CR)a, n (%) | 158 (44.5%) | 123 (34.7%) |
| 95% CI (%)b | (39.3%, 49.9%) | (29.8%, 40.0%) |
| MRD negativity ratea,c,d, n (%) | 204 (57.5%) | 115 (32.5%) |
| 95% CI (%)b | (52.1%, 62.7%) | (27.6%, 37.6%) |
| MRD negativity rate in patients with CR or betterc,e | ||
| Number of patients with CR or better | n=158 | n=123 |
| MRD negativity rate n (%) | 121 (76.6%) | 72 (58.5%) |
| 95% CI (%)b | (69.2%, 82.9%) | (49.3%, 67.3%) |
| VRd = bortezomib-lenalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval a Based on intent-to-treat population b Exact 95% confidence interval c Based on threshold of 10-5 using a next-generation sequencing assay (clonoSEQ) d Patients achieved both MRD negativity (threshold of 10-5) and response of CR or better e Based on patients with CR or better response by the end of consolidation |
||
The efficacy of DARZALEX FASPRO with bortezomib, melphalan and prednisone was evaluated in a single-arm cohort of PLEIADES (NCT03412565), a multi-cohort, open-label trial. Eligible patients were required to have newly diagnosed multiple myeloma who are ineligible for transplant. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 6, once every 3 weeks from weeks 7 to 54 and once every 4 weeks starting with week 55 until disease progression or unacceptable toxicity; bortezomib 1.3 mg/m² subcutaneously twice weekly on Weeks 1, 2, 4 and 5 for the first 6-week cycle (Cycle 1; 8 doses), followed by once weekly on Weeks 1, 2, 4 and 5 for eight more 6-week cycles (Cycles 2Â9; 4 doses per cycle); and melphalan 9 mg/m² and prednisone 60 mg/m² orally on Days 1 to 4 of the nine 6-week cycles (Cycles 1-9). The major efficacy outcome measure was overall response rate (ORR).
A total of 67 patients received DARZALEX FASPRO with VMP. The median age was 75 years (range: 66 to 86 years); 46% were male; 69% were White, 8% Asian, and 2% Black or African American; and 33% had ISS Stage I, 45% had ISS Stage II, and 22% had ISS Stage III disease.
Efficacy results are summarized in Table 23. The median duration of follow-up for patients was 6.9 months.
Table 23: Efficacy Results from PLEIADES in Patients Who Received DARZALEX FASPRO-VMP
| DARZALEX FASPRO-VMP (N=67) |
|
| Overall response rate (sCR+CR+VGPR+PR), n (%)a | 59 (88%) |
| 95% CI (%) | (78%, 95%) |
| Stringent complete response (sCR) | 5 (8%) |
| Complete response (CR) | 7 (10%) |
| Very good partial response (VGPR) | 31 (46%) |
| Partial response (PR) | 16 (24%) |
| CI=confidence interval a Based on treated patients |
|
The efficacy of DARZALEX FASPRO with lenalidomide and dexamethasone (DARZALEX FASPRO-Rd) was evaluated in a single-arm cohort of PLEIADES (NCT03412565), a multi-cohort, open-label trial. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity with lenalidomide 25 mg once daily orally on Days 1-21 of each 28-day cycle; and dexamethasone 40 mg per week (or a reduced dose of 20 mg per week for patients >75 years or BMI <18.5). The major efficacy outcome measure was ORR.
A total of 65 patients received DARZALEX FASPRO with Rd. The median age was 69 years (range: 33 to 82 years); 69% were male; 69% were White, and 3% Black or African American; and 42% had ISS Stage I, 30% had ISS Stage II, and 28% had ISS Stage III disease. Patients had received a median of 1 prior line of therapy. A total of 52% of patients had a prior ASCT; 95% of patients received a prior PI; 59% received a prior immunomodulatory agent, including 22% who received prior lenalidomide; and 54% of patients received both a prior PI and immunomodulatory agent.
Efficacy results are summarized in Table 24. The median duration of follow-up for patients was 7.1 months.
Table 24: Efficacy Results from PLEIADES in Patients Who Received DARZALEX FASPRO-Rd
| DARZALEX FASPRO-Rd (N=65) |
|
| Overall response rate (sCR+CR+VGPR+PR), n (%)a | 59 (91%) |
| 95% CI (%) | (81%, 97%) |
| Stringent complete response (sCR) | 4 (6%) |
| Complete response (CR) | 8 (12%) |
| Very good partial response (VGPR) | 30 (46%) |
| Partial response (PR) | 17 (26%) |
| CI=confidence interval a Based on treated patients |
|
The efficacy of DARZALEX FASPRO with pomalidomide and dexamethasone (DARZALEX FASPRO-Pd) versus pomalidomide and dexamethasone (Pd) alone was evaluated in APOLLO (NCT03180736), an open-label, randomized, active-controlled trial. Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or unacceptable toxicity with pomalidomide 4 mg once daily orally on Days 1-21 of each 28-day cycle; and dexamethasone 40 mg per week (or a reduced dose of 20 mg per week for patients >75 years). The major efficacy outcome measure was progression-free survival (PFS).
A total of 304 patients were randomized: 151 to the DARZALEX FASPRO-Pd arm and 153 to the Pd arm. The median age was 67 years (range: 35 to 90); 53% were male and 89% were White, <1% were Black or African American, and <1% were Asian, and 45% had ISS Stage I, 33% had ISS Stage II, and 22% had ISS Stage III disease. Patients had received a median of 2 prior lines of therapy (range 1-5), with 11% of patients having received 1 prior line of therapy and 75% of patients having received 2-3 prior lines of therapy. All patients received a prior treatment with a PI and lenalidomide, and 56% of patients received prior ASCT. The majority of patients were refractory to lenalidomide (80%), a PI (48%), or both an immunomodulatory agent and a PI (42%).
APOLLO demonstrated an improvement in PFS in the DARZALEX FASPRO-Pd treatment group as compared to the Pd treatment group; the median PFS was 12.4 months in the DARZALEX FASPRO-Pd treatment group and 6.9 months in the Pd treatment group (HR [95% CI]: 0.63 [0.47, 0.85]; p-value = 0.0018), representing a 37% reduction in the risk of disease progression or death for patients treated with DARZALEX FASPRO-Pd versus Pd.
Figure 2: Kaplan-Meier Curve of PFS in APOLLO
 |
Additional efficacy results from APOLLO are presented in Table 25.
Table 25: Efficacy Results from APOLLOa
| DARZALEX FASPRO-Pd (n=151) |
Pd (n=153) |
|
| Overall response (sCR+CR+VGPR+PR) n (%)a | 104 (68.9%) | 71 (46.4%) |
| P-valueb | <0.0001 | |
| Stringent complete response (sCR) | 14 (9.3%) | 2 (1.3%) |
| Complete response (CR) | 23 (15.2%) | 4 (2.6%) |
| Very good partial response (VGPR) | 40 (26.5%) | 24 (15.7%) |
| Partial response (PR) | 27 (17.9%) | 41 (26.8%) |
| MRD negativity ratec,e n (%) | 13 (8.6%) | 3 (2.0%) |
| 95% CI (%) | (4.7%, 14.3%) | (0.4%, 5.6%) |
| P-valued | 0.0 | 102 |
| MRD negativity rate in patients with CR or bettere | ||
| Number of patients with CR or better | N=37 | N=6 |
| MRD negativity rate n (%) | 13 (35.1%) | 3 (50.0%) |
| 95% CI (%) | (20.2%, 52.5%) | (11.8%, 88.2%) |
| Pd=pomalidomide-dexamethasone; MRD=minimal residual disease; CI=confidence interval a Based on intent-to-treat population b p-value from Cochran Mantel-Haenszel Chi-Squared test adjusted for stratification factors c Based on the intent-to-treat population d p-value from Fisher’s exact test. e Based on threshold of 10-5 using a next-generation sequencing assay (clonoSEQ). |
||
In responders, the median time to response was 1 month (range: 0.9 to 9.1 months) in the DARZALEX FASPRO-Pd group and 1.9 months (range: 0.9 to 17.3 months) in the Pd group. The median duration of response had not been reached in the DARZALEX FASPRO-Pd group (range: 1 to 34.9+ months) and was 15.9 months (range: 1+ to 24.8 months) in the Pd group.
With a median follow-up of 16.9 months, 99 deaths were observed; 48 in the DARZALEX FASPRO-Pd group and 51 in the Pd group. Median OS was not reached for either treatment group.
The efficacy of DARZALEX FASPRO with carfilzomib and dexamethasone (DARZALEX FASPRO-Kd) was evaluated in a single-arm cohort of PLEIADES (NCT03412565), a multi-cohort, open-label trial. This cohort enrolled patients with relapsed or refractory multiple myeloma excluding patients with left ventricular ejection fraction (LVEF) less than 40%, myocardial infarction within 6 months, uncontrolled cardiac arrhythmia, or uncontrolled hypertension (systolic blood pressure >159 mmHg or diastolic >99 mmHg despite optimal treatment). Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously once weekly from Weeks 1 to 8, once every 2 weeks from Weeks 9 to 24 and once every 4 weeks starting with Week 25 until disease progression or unacceptable toxicity with carfilzomib administered by IV infusion at a dose of 20 mg/m² on Cycle 1 Day 1 and if a dose of 20 mg/m² was tolerated, carfilzomib was administered at a dose of 70 mg/m² as a 30-minute IV infusion, on Cycle 1 Day 8 and Day 15, and then Day 1, 8 and 15 of each cycle and dexamethasone 40 mg per week (or a reduced dose of 20 mg per week for patients ≥75 years or BMI <18.5). The major efficacy outcome measure was ORR.
A total of 66 patients received DARZALEX FASPRO with Kd. The median age was 61 years (range: 42 to 84); 52% were male; 73% were White and 3% Black or African American; and 68% had ISS Stage I, 18% had ISS Stage II, and 14% had ISS Stage III disease. A total of 79% of patients had a prior ASCT; 91% of patients received a prior PI. All patients received 1 prior line of therapy with exposure to lenalidomide and 62% of patients were refractory to lenalidomide.
Efficacy results are summarized in Table 26. At a median follow-up of 9.2 months, the median duration of response had not been reached and an estimated 85.2% (95% CI: 72.5, 92.3) maintained response for at least 6 months and 82.5% (95% CI: 68.9, 90.6) maintained response for at least 9 months.
Table 26: Efficacy Results from PLEIADES in Patients Who Received DARZALEX FASPRO-Kd
| DARZALEX FASPRO-Kd (N=66) |
|
| Overall response rate (sCR+CR+VGPR+PR), n (%)a | 56 (84.8%) |
| 95% CI (%) | (73.9%, 92.5%) |
| Stringent complete response (sCR) | 11 (16.7%) |
| Complete response (CR) | 14 (21.2%) |
| Very good partial response (VGPR) | 26 (39.4%) |
| Partial response (PR) | 5 (7.6%) |
| CI=confidence interval a Based on treated patients |
|
The efficacy of DARZALEX FASPRO as monotherapy was evaluated in COLUMBA (NCT03277105), an open-label, randomized, non-inferiority study. Eligible patients were required to have relapsed or refractory multiple myeloma who had received at least 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent or who were double-refractory to a proteasome inhibitor and an immunomodulatory agent. Patients were randomized to receive DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously or daratumumab 16 mg/kg administered intravenously; each administered once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until unacceptable toxicity or disease progression. The major efficacy outcome measures were ORR by the IMWG response criteria and maximum Ctrough at pre-dose Cycle 3 Day 1 [see CLINICAL PHARMACOLOGY]. Randomization was stratified by body weight, myeloma type, and number of prior lines of therapy.
A total of 522 patients were randomized: 263 to the DARZALEX FASPRO arm and 259 to the intravenous daratumumab arm. The median age was 67 years (range: 33 to 92 years); 55% were male; and 78% were White, 14% Asian, and 3% Black or African American. The median weight was 73 kg (range: 29 to 138). Patients had received a median of 4 prior lines of therapy. A total of 51% of patients had a prior ASCT; 100% of patients received both a PI and an immunomodulatory agent. Forty-nine percent of patients were refractory both a PI and an immunomodulatory agent. Eighty-two percent of patients were refractory to their last line of prior systemic therapy.
The results show that DARZALEX FASPRO 1,800 mg/30,000 units administered subcutaneously is non-inferior to daratumumab 16 mg/kg administered intravenously in terms of ORR and maximum trough concentration [see CLINICAL PHARMACOLOGY]. Median progression-free survival was 5.6 months in the DARZALEX FASPRO arm and 6.1 months in the intravenous daratumumab arm. ORR results are provided in Table 27.
Table 27: Efficacy Results from COLUMBA
| DARZALEX FASPRO (N=263) |
Intravenous Daratumumab (N=259) |
|
| Overall response (sCR+CR+VGPR+PR), n (%)a | 108 (41%) | 96 (37%) |
| 95% CI (%) | (35%, 47%) | (31%, 43%) |
| Ratio of response rates (95% CI) | 1.11 (0.89, 1.37) | |
| CR or better, n (%) | 5 (1.9%) | 7 (2.7%) |
| Very good partial response (VGPR) | 45 (17%) | 37 (14%) |
| Partial response (PR) | 58 (22%) | 52 (20%) |
| a Based on intent-to-treat population. | ||
The efficacy of DARZALEX FASPRO with VCd was evaluated in ANDROMEDA (NCT03201965), an open-label, randomized, active-controlled trial. Eligible patients were required to have newly diagnosed light chain (AL) amyloidosis with at least one affected organ, measurable hematologic disease, Cardiac Stage I-IIIA (based on European Modification of Mayo 2004 Cardiac Stage), and NYHA Class I-IIIA. Patients with NYHA Class IIIB and IV were excluded. Patients were randomized to receive bortezomib 1.3 mg/m² administered subcutaneously, cyclophosphamide 300 mg/m² (max dose 500 mg) administered orally or intravenously, and dexamethasone 40 mg (or a reduced dose of 20 mg for patients >70 years or body mass index <18.5 or who have hypervolemia, poorly controlled diabetes mellitus or prior intolerance to steroid therapy) administered orally or intravenously on Days 1, 8, 15, and 22 of each 28-day cycle with or without DARZALEX FASPRO 1,800 mg/30,000 units subcutaneously once weekly from weeks 1 to 8, once every 2 weeks from weeks 9 to 24 and once every 4 weeks starting with week 25 until disease progression or a maximum of two years. When DARZALEX FASPRO and dexamethasone were administered on the same day, dexamethasone 20 mg was administered before DARZALEX FASPRO with the remaining dose of dexamethasone administered after DARZALEX FASPRO if applicable. The major efficacy outcome measure was confirmed hematologic complete response (HemCR) rate based on Consensus Criteria as determined by the Independent Review Committee (negative serum and urine immunofixation, involved free light chain level decrease to less than the upper limit of normal, and normal free light chain ratio). Randomization was stratified by Cardiac Stage (European Modification of Mayo 2004 Cardiac Stage) countries that typically offer autologous stem cell transplant (ASCT) for patients with light chain (AL) amyloidosis, and renal function.
A total of 388 patients were randomized: 195 to DARZALEX FASPRO-VCd and 193 to VCd. The median patient age was 64 years (range: 34 to 87 years); 58% were male; 76% White, 17% Asian, and 3% Black or African American; 23% had light chain (AL) amyloidosis Cardiac Stage I, 40% had Stage II, and 37% had Stage IIIA. The median number of organs involved was 2 (range: 1-6) and 66% of patients had 2 or more organs involved. Vital organ involvement was: cardiac 71%, renal 59% and hepatic 8%. The majority (79%) of patients had lambda free light chain disease.
Efficacy results are summarized in Table 28.
Table 28: Efficacy Results from ANDROMEDAa
| DARZALEX FASPRO-VCd (n=195) |
VCd (n=193) |
|
| Hematologic complete response (HemCR), n (%) | 82 (42%) | 26 (13%) |
| p-valueb | <0.0001 | |
| Very good partial response (VGPR), n (%) | 71 (36%) | 69 (36%) |
| Partial response (PR), n (%) | 26 (13%) | 53 (27%) |
| Hematologic VGPR or better (HemCR + VGPR), n (%) | 153 (78%) | 95 (49%) |
| Major organ deterioration progression-free survivalc, Hazard ratio with 95% CI | 0.58 (0.37, 0.92) | |
| VCd=bortezomib-cyclophosphamide-dexamethasone aBased on intent-to-treat population bp-value from Cochran Mantel-Haenszel Chi-Squared test. cMajor organ deterioration-PFS defined as hematologic progression, major organ (cardiac or renal) deterioration or death |
||
The median time to HemCR was 59 days (range: 8 to 299 days) in the DARZALEX FASPRO-VCd arm and 59 days (range: 16 to 340 days) in the VCd arm. The median time to VGPR or better was 17 days (range: 5 to 336 days) in the DARZALEX FASPRO-VCd arm and 25 days (range: 8 to 171 days) in the VCd arm. The median duration of HemCR had not been reached in either arm.
The median follow-up for the study is 11.4 months. Overall survival (OS) data were not mature. A total of 56 deaths were observed [N=27 (13.8%) DARZALEX FASPRO-VCd vs. N=29 (15%) VCd group].
DARZALEX
(Dar'-zah-lex)
FASPRO®
(Fas-pro)
(daratumumab and hyaluronidase-fihj) injection, for subcutaneous use
DARZALEX FASPRO may be used with other medicines called lenalidomide, thalidomide or pomalidomide. You should also read the Medication Guide that comes with lenalidomide, thalidomide or pomalidomide if you use DARZALEX FASPRO with these medicines.
What is DARZALEX FASPRO?
DARZALEX FASPRO is a prescription medicine used to treat adult patients with multiple myeloma:
DARZALEX FASPRO is a prescription medicine also used in combination with the medicines bortezomib, cyclophosphamide and dexamethasone in patients with newly diagnosed light chain (AL) amyloidosis.
It is not known if DARZALEX FASPRO is safe and effective in children.
Do not receive DARZALEX FASPRO if you have a history of a severe allergic reaction to daratumumab, hyaluronidase or any of the ingredients in DARZALEX FASPRO. See the end of this leaflet for a complete list of ingredients in DARZALEX FASPRO.
Before you receive DARZALEX FASPRO, tell your healthcare provider about all of your medical conditions, including if you:
Before you receive DARZALEX FASPRO for light chain (AL) amyloidosis, tell your healthcare provider if you have a history of heart problems. DARZALEX FASPRO should not be used in light chain (AL) amyloidosis patients with highly advanced heart disease outside of clinical trials.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive DARZALEX FASPRO?
If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.
What are the possible side effects of DARZALEX FASPRO?
DARZALEX FASPRO may cause serious reactions, including:
The most common side effects of DARZALEX when used alone include: cold-like symptoms (upper respiratory infection) and decreased red blood cell counts.
The most common side effects of DARZALEX FASPRO when used in combination therapy include:
These are not all of the possible side effects of DARZALEX FASPRO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
General information about the safe and effective use of DARZALEX FASPRO.
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about DARZALEX FASPRO that is written for health professionals.
What are the ingredients in DARZALEX FASPRO?
Active ingredient: daratumumab and hyaluronidase-fihj
Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 20, sorbitol, and water for injection.
This Patient Information has been approved by the U.S. Food and Drug Administration.
